RNA

RNA is currently a 'Special Situation' arbitrage play, pinned to its $72.00/share acquisition offer from Novartis, which explains the extremely low 2.5% annualized volatility ('Quiet Storm'). The stock is trading at a premium ($72.92) because of the imminent spin-off of its cardiology assets (Atrium Therapeutics) to existing shareholders. The 'Alpha Male' and 'Steady Climb' signals are not tracking organic growth, but rather the market's pricing of the Spin-Co stub (implied value ~$0.92) and institutional positioning ahead of the distribution.